ClinicalTrials.gg
RecruitingNCT07035847Updated Feb 27, 2026

Transaxillary TAVR With Solely Echocardiography Guidance

An interventional study of Echocardiography guided TAVR in Aortic Stenosis, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2024, registered May 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
40th of 47
20 · median 120
Started
2024
with 10 others
No phase
37 of 69
20 open now
Primary completion
2026-12
later than 28 of 50 live
Registered
52nd of 69
by date
Lead sponsor
4 of 69
Chinese Academy of Medical Sciences, Fuwai Hospital

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 40th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 37 with no phase, reaches primary completion later than 28 of the 50 other live ones, and was the 52nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and feasibility of performing transaxillary transcatheter aortic valve replacement (TA TAVR) guided solely by echocardiography in patients with severe aortic stenosis (AS).

03

Conditions studied

  • Aortic Stenosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2)
  2. suitable for Transaxillary TAVR

Exclusion criteria

Exclusion Criteria:

  1. required hybrid procedures or concomitant interventions on other cardiac malformations
  2. inoperable due to extremely high surgical risk or severe comorbidities
  3. untreated (>70% obstruction) proximal vessel coronary vascular disease amenable to revascularization
  4. previously undergone aortic valve replacement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Echo guided TAVR

    Patients received Echocardiography guided TAVR

    Procedure: Echocardiography guided TAVR

Interventions

  • ProcedureEchocardiography guided TAVR

    Echocardiography guided TAVR

06

What researchers measure

Primary outcomes

  1. Valve Academic Research Consortium-3

    Outcomes were reported according to the VARC-3 criteria.Which include: Technical success: Evaluated immediately post-procedure (e.g., successful vascular access, device delivery, deployment, no immediate complications). Device success: Includes successful valve function with acceptable hemodynamics and positioning. Procedural success: Includes 30-day outcomes, combining technical/device success and absence of major complications.

    Time frame: 30 days after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 26 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
Jun 25, 2025
StartActual
Oct 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07035847
Responsible party
Pan Xiangbin (Principle Investigator, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Jun 25, 2025
Start date
Oct 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Xiangbin Pan, MD
Contact
panxiangbin@fuwaihospital.org
+8688396666
Xu Wang, MD
Contact
+86 88396655
Xiangbin Pan, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital
Xu Wang, MD
study director · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion